Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galunisertib - Eli Lilly

Drug Profile

Galunisertib - Eli Lilly

Alternative Names: LY-2157299

Latest Information Update: 16 Aug 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer AstraZeneca; Eli Lilly; National Cancer Institute (USA); University of Oklahoma; Vanderbilt-Ingram Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Pyrazoles; Pyridines; Pyrroles; Quinolines; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Colorectal cancer; Glioblastoma; Glioma; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer; Sarcoma; Solid tumours

Most Recent Events

  • 30 Jul 2019 Discontinued - Phase-I for Breast cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (Eli Lilly Pipeline - July 2019)
  • 30 Jul 2019 Discontinued - Phase-I for Cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) (Eli Lilly Pipeline - July 2019)
  • 30 Jul 2019 Discontinued - Phase-I for Liver cancer (Combination therapy, Inoperable/Unresectable) in Japan (PO) (Eli Lilly Pipeline - July 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top